SCHEMBL6568237

SCHEMBL6568237

O=C(NN=Cc1cc(O)ccc1O)c1cccc2ccccc12

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.77
MEN1 O00255 6/20 0.77
NPC1 O15118 2/20 0.77
RAB9A P51151 2/20 0.77
GCGR P47871 2/20 0.61
MGAM O43451 1/20 0.61
GAA P10253 1/20 0.61
SI P14410 1/20 0.61
MGAM2 Q2M2H8 1/20 0.61
NTRK1 P04629 1/20 0.60
MCL1 Q07820 1/20 0.59
GUSB P08236 1/20 0.58
AR P10275 2/20 0.57
RRM1 P23921 1/20 0.57
PGR P06401 1/20 0.57
POLB P06746 1/20 0.57
KDM4E B2RXH2 2/20 0.56
TDP1 Q9NUW8 2/20 0.56
LMNA P02545 1/20 0.56
HSP90AA1 P07900 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6568234 1.00 KMT2A (0.77) KMT2AMEN1NPC1RAB9AGCGR
SCHEMBL10064203 0.88 KDM4E (0.61) KMT2AMEN1NPC1RAB9AMGAM
SCHEMBL14983736 0.85 AR (0.80) KMT2AMEN1NPC1RAB9AGCGR
SCHEMBL21292803 0.84 MEN1 (1.00) KMT2AMEN1NPC1RAB9ARRM1
SCHEMBL21292805 0.84 MEN1 (1.00) KMT2AMEN1NPC1RAB9ARRM1
SCHEMBL22245273 0.82 GCGR (0.76) KMT2AMEN1NPC1RAB9AGCGR
SCHEMBL20115427 0.82 GCGR (0.76) KMT2AMEN1NPC1RAB9AGCGR
SCHEMBL6570164 0.82 KDM4E (0.77) KMT2AMEN1GCGRMGAMGAA
SCHEMBL6570171 0.82 KDM4E (0.77) KMT2AMEN1GCGRMGAMGAA
SCHEMBL1563058 0.82 KMT2A (0.67) KMT2AMEN1NPC1RAB9AGCGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040110963-A1 Novel hydrazones ARPIDA AG (CH) 2004-06-10 US claimed
US-20040110963-A1 Novel hydrazones ARPIDA AG (CH) 2004-06-10 US disclosed
EP-1404644-A2 NOVEL HYDRAZONES Arpida AG, (CH) 2004-04-07 EP disclosed
WO-2002070464-A2 HYDRAZONES AND THEIR THERAPEUTIC USE ARPIDA AG (CH) 2002-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110963-A1 Novel hydrazones H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HK1, MPO KMT2A 3368/4885MEN1 2514/4885NPC1 785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.